Growth stocks for the next decade? We talk Pro Medicus, Afterpay, Audinate and two burns companies
Claude Walker joins us in a deep dive into some of the most talked about growth stocks on the ASX.
We talk about our investment mistakes, some of the one that have worked out, and how to assess investments when so much of their value lies in the future.
0:38 - Claude's background and time at Motley Fool
4:30 - Pro Medicus (PME:ASX) recommendation and discussion
6:38 - Claude touches on his investment style
8:08 - Pro Medicus as a platform business rather than just a software business
8:30 - Pro Medicus - the numbers
10:20 - Claude dives into Pro Medicus' two key revenue streams
11:50 - Michael introduces Alteryx (AYX:NYSE) and accounting standards
14:45 - Claude's worst mistake (Touchcorp)
17:30 - Claude touches on cognitive errors
18:10 - Michael discusses Afterpay (APT:ASX), comparing it to some US tech investments
19:25 - Afterpay, the YOLO stock?
21:55 - The network effects of Afterpay
22:30 - Consumer behaviour of Afterpay customers
24:38 - Claude introduces Avita Healthcare (AVH:ASX), discussed in Frazis Capital's previous podcast
26:58 - Avita's opportunity in vitiligo and skin rejuvenation
29:59 - How to value a company like Avita when there are no conventional cashflows?
32:02 - When should you sell a company like Avita?
35:20 - BARDA's funding of Polynovo (PNV:ASX) and Avita
37:40 - Claude goes through Audinate (AD8:ASX)
41:55 - Audinate's financial numbers
45:00 - Audinate's next 5 years
48:00 - Claude talks about his new project, "A Rich Life"
5 stocks mentioned
Michael manages a global equity investment fund focused on technology and the life sciences. Michael completed undergraduate and graduate chemistry degrees at Magdalen College, Oxford University, and studied finance at the London School of Economics